Fluticasone propionate/salmeterol (Advair)
Pronunciation: flue-TIK-a-sone proe-pee-oh-nate / sal-MET-er-ol.
- Generic name
- fluticasone propionate/salmeterol
- Brand names
- United States: ADVAIR DISKUS, United States: Advair HFA, United States: AirDuo RespiClick, United Kingdom: AirFluSal MDI
- Drug class
- Fixed-dose inhaled corticosteroid (fluticasone propionate) and long-acting beta2-agonist (salmeterol) combination
- Form
- Device-specific inhaler products, including a dry-powder inhaler and a pressurised metered-dose inhaler
- Route
- Oral inhalation
- Legal status
- Prescription-only medicine
Supply Rules Vary
Trade names by country: United States · United Kingdom
Australia: · Full directory
What fluticasone propionate/salmeterol is and how it works
Fluticasone propionate/salmeterol combines fluticasone, which reduces airway swelling, with salmeterol, a long-acting beta2-agonist that relaxes and opens air passages. It controls symptoms but does not cure the underlying condition. (1) (2) (3)
This combination is maintenance treatment and is not a rescue inhaler for a sudden asthma or COPD attack. The exact authorised use, age range, strength, and inhaler instructions depend on the specific country product and device. A clinician selects the product and strength; the prescription label and product instructions control individual use.
Mechanism of action: how fluticasone propionate/salmeterol works
Fluticasone propionate is an inhaled corticosteroid that reduces airway swelling. Salmeterol is a long-acting beta2-agonist that relaxes and opens air passages. (1) (2) (3)
What fluticasone propionate/salmeterol is used for
Asthma
In the United States, ADVAIR DISKUS is labelled for twice-daily treatment of asthma in people aged 4 years and older. UK AirFluSal MDI is described for adults aged 18 years and older with asthma where an inhaled corticosteroid/long-acting beta2-agonist combination is appropriate. These product-specific age ranges and indications must not be transferred between devices or countries. (1) (3)
Chronic obstructive pulmonary disease (COPD)
US ADVAIR DISKUS is labelled for maintenance treatment of airflow obstruction and reduction of exacerbations in COPD. This supplied source set does not establish COPD use for UK AirFluSal MDI or for other fluticasone/salmeterol devices. (1) (3)
Before taking fluticasone propionate/salmeterol
Do not take / not appropriate for
- Do not use US ADVAIR DISKUS as the primary treatment for status asthmaticus or another acute asthma or COPD episode requiring intensive measures. (US ADVAIR DISKUS) (1)
- Do not use US ADVAIR DISKUS if there has been severe hypersensitivity to milk proteins, fluticasone propionate, salmeterol, or an excipient. The DISKUS contains lactose. (US ADVAIR DISKUS) (1)
Tell your clinician about
- Any allergy or prior reaction to milk proteins, fluticasone, salmeterol, or an inhaler ingredient.
- Any worsening breathing, recent attacks, how often a rescue inhaler is needed, and whether it is working less well.
- All medicines, including other inhaled or oral asthma/COPD medicines, beta-blockers, diuretics, antidepressants, and medicines that may affect CYP3A4.
- Current or recent infection, fever or chills, eye symptoms, bone-health concerns, cardiovascular conditions, or endocrine conditions.
- Pregnancy, plans for pregnancy, or breastfeeding.
- For a child, growth concerns and use of the exact prescribed inhaler.
How to take fluticasone propionate/salmeterol
- Use only the exact prescribed inhaler, strength, and schedule, following its prescription label and manufacturer instructions.
- Ask a doctor, pharmacist, or respiratory therapist to demonstrate use of the specific inhaler. Do not assume that instructions for a dry-powder inhaler apply to a pressurised metered-dose inhaler, or vice versa.
- Do not use it more often than prescribed and do not use another medicine containing a long-acting beta2-agonist without prescriber or pharmacist review.
- Do not change other inhaled or oral medicines, or stop this medicine, unless the healthcare provider directs this.
- For US ADVAIR DISKUS, rinse the mouth with water and spit it out after each dose to help reduce mouth and throat thrush.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3)
Missed dose
If a dose is missed, skip it and continue the regular schedule. Do not inhale a double dose. If there is uncertainty about the schedule for the exact product, contact the prescriber or pharmacist.
Overdose
If more than the prescribed amount may have been inhaled, contact the prescriber or pharmacist for product-specific advice. Seek urgent or emergency care for severe breathing difficulty, fainting, chest pain, a fast or irregular heartbeat, swelling, or a suspected severe allergic reaction. (1) (2)
Side effects
Reported effects vary by condition, age group, product, and study. Rinsing and spitting after use can help reduce mouth and throat thrush but does not prevent every adverse effect.
Mouth or throat effects
What to notice: Thrush, white patches in the mouth, pharyngitis or throat irritation, hoarseness, or voice change.
What to do: Tell the prescribing team about white patches, persistent throat symptoms, or troublesome voice changes. (1) (2) (3)
Respiratory, stomach, pain, or general symptoms
What to notice: Upper respiratory infection, bronchitis, cough, headache, nausea or vomiting, or musculoskeletal pain.
What to do: Discuss persistent, worsening, or troublesome symptoms with the prescribing team. (1)
Worsening respiratory control or airway symptoms after inhalation
What to notice: New wheeze or chest tightness after inhalation; breathing that worsens; needing a rescue inhaler more often; or a rescue inhaler working less well.
What to do: Get medical care promptly for assessment. Sudden or severe breathing difficulty requires urgent or emergency care. (1) (2)
Possible infection, eye, or systemic corticosteroid-related concern
What to notice: Fever, chills, other infection signs, or new concerning eye symptoms.
What to do: Contact a clinician promptly for assessment. (1) (2)
Serious warnings
Acute asthma or COPD attack — emergency
Symptoms: Sudden or severe breathing difficulty, rapidly worsening breathing, or inadequate relief from the prescribed rescue inhaler.
Action: Use the prescribed rescue plan and seek urgent or emergency care as appropriate. This medicine is not a rescue inhaler. (1) (2)
Immediate hypersensitivity reaction — emergency
Symptoms: Hives or rash, swelling, choking or difficulty swallowing, noisy breathing, fainting, or other suspected severe allergic-reaction symptoms.
Cardiovascular effects — urgent
Symptoms: Fast, pounding, or irregular heartbeat, chest pain, or fainting.
Action: Seek urgent medical assessment; call emergency services for severe symptoms or fainting. (1) (2)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Strong CYP3A4 inhibitors | Systemic corticosteroid and cardiovascular adverse effects may increase with strong CYP3A4 inhibitors, including examples such as ritonavir, atazanavir, clarithromycin, itraconazole, ketoconazole, and related medicines. | Ask the prescriber or pharmacist to check the individual medicine list; these combinations are not recommended for US ADVAIR DISKUS. (1) |
| Other long-acting beta2-agonist-containing medicines | Adding another long-acting beta2-agonist-containing medicine can create a safety concern. LABA monotherapy has serious asthma-related risk; this product is a fixed inhaled corticosteroid/LABA combination. | Do not add another LABA-containing medicine without clinician or pharmacist review. (1) |
| MAO inhibitors, tricyclic antidepressants, beta-blockers, and non-potassium-sparing diuretics | MAO inhibitors and tricyclic antidepressants require extreme caution. Beta-blockers can reduce bronchodilator effect and may cause severe bronchospasm. Non-potassium-sparing diuretics may worsen ECG changes and/or low potassium with beta-agonists. | Provide a complete medicine list to the prescriber and pharmacist for review before treatment changes. (1) (3) |
Pregnancy, breastfeeding, kidney/liver function, age
Children and adolescents
US ADVAIR DISKUS is labelled for asthma from age 4 years, while the supplied UK AirFluSal MDI information describes adults aged 18 years and older with asthma. Children may grow more slowly with inhaled corticosteroid treatment; clinicians monitor growth. Do not extrapolate an adult product or device to a child. (1) (2) (3)
Pregnancy and breastfeeding
Discuss pregnancy, plans for pregnancy, or breastfeeding with the treating clinician. (2)
People with infection, eye, bone, cardiovascular, or endocrine concerns
The product information includes infection and immunosuppression, pneumonia, adrenal suppression and other systemic corticosteroid effects, reduced bone mineral density, glaucoma or cataracts, hypokalemia or hyperglycemia, and selected cardiovascular or endocrine conditions as areas requiring clinician assessment and monitoring. (1) (2)
Monitoring
Before starting
- Confirm the diagnosis, intended indication, age eligibility, exact country product, device, and prescribed strength.
- Review rescue-inhaler needs, current respiratory control, all medicines, allergy history, infection concerns, and relevant cardiovascular or endocrine conditions.
- Provide training for the exact inhaler; do not substitute dry-powder and pressurised metered-dose inhaler instructions.
During treatment
- Review respiratory control, worsening breathing, rescue-inhaler use, inhaler technique, adherence, and adverse effects.
- Assess for oral candidiasis, infection or pneumonia concerns, systemic corticosteroid effects, bone health, vision changes, and relevant potassium or glucose concerns when clinically indicated.
- Monitor growth in children receiving inhaled corticosteroid treatment.
- Review whether the prescribed device and current treatment remain appropriate; any change requires prescriber or pharmacist assessment.
Storage
For US ADVAIR DISKUS only: store at 20–25°C (68–77°F), dry, away from heat and sunlight, and in the unopened foil pouch until ready to use. Keep the device dry. Discard the DISKUS one month after opening the foil pouch or when its counter is zero, whichever occurs first. Do not generalise these instructions to another device or market.
Professional information
Clinician-facing context only. Use current local product information for the exact device, indication, authorised age range, strength, administration instructions, contraindications, interactions, and monitoring requirements.
United States
Indication: ADVAIR DISKUS asthma and COPD indications
Dose summary: ADVAIR DISKUS is a dry-powder inhaler with foil blisters labelled 100, 250, or 500 micrograms fluticasone propionate with 50 micrograms salmeterol. The label describes twice-daily treatment for its authorised indications. This page does not provide an individual dose; the clinician selects the prescribed strength and the prescription label controls use.
Renal context: Renal dosing information was not established by the supplied source set. (1)
United Kingdom
Indication: AirFluSal MDI asthma
Dose summary: AirFluSal MDI 25 micrograms/125 micrograms per metered actuation is described for adults aged 18 years and older with asthma where an inhaled corticosteroid/LABA combination is appropriate. Each delivered dose contains 21 micrograms salmeterol and 110 micrograms fluticasone propionate. It is not interchangeable with ADVAIR DISKUS without prescriber or pharmacist review.
Renal context: Renal dosing information was not established by the supplied source set. (3)
Australia, Canada, New Zealand, and European Union markets
Indication: Availability, brands, authorised uses, and dosing (1) (2) (3)
Hepatic guidance
Hepatic impairment-specific dosing was not established by the supplied source set.
Overdose note
If excess inhalation is suspected, obtain product-specific advice from the prescriber or pharmacist and assess urgent symptoms including severe breathing difficulty, chest pain, fainting, arrhythmia symptoms, or severe allergic reaction. (1) (2) (3)
Frequently asked questions
Is Advair DISKUS a rescue inhaler?
No. US ADVAIR DISKUS is not for relief of acute bronchospasm, and fluticasone/salmeterol inhalation is not for a sudden asthma or COPD attack. Use the clinician-provided rescue plan for attacks. (1) (2)
Are Advair DISKUS and AirFluSal MDI interchangeable?
This page cannot say that they are interchangeable. ADVAIR DISKUS is a US dry-powder inhaler, while AirFluSal is a UK pressurised metered-dose inhaler. Their strengths and instructions differ, so a prescriber or pharmacist must review any proposed device change. (1) (3)
What should I do if I miss a dose?
Skip the missed dose and continue the regular schedule. Do not inhale a double dose. Ask the prescriber or pharmacist if the schedule for the exact inhaler is unclear. (2)
Why should I rinse my mouth after using ADVAIR DISKUS?
The US ADVAIR DISKUS patient information says to rinse the mouth with water and spit it out after each dose to help reduce mouth and throat thrush. Other inhalers have their own product instructions. (1) (3)
What is the mechanism of action of fluticasone propionate/salmeterol?
Fluticasone propionate is an inhaled corticosteroid that reduces airway swelling. Salmeterol is a long-acting beta2-agonist that relaxes and opens air passages. (1) (2) (3)
References
- ADVAIR DISKUS — prescribing information and patient informationU.S. National Library of Medicine DailyMed; current FDA prescribing information and patient information · United States · dated 2026-03-30 · accessed not_supplied_in_research_notes · source 1
- Fluticasone and Salmeterol Oral InhalationMedlinePlus, U.S. National Library of Medicine · United States · dated 2025-10-15 · accessed not_supplied_in_research_notes · source 2
- AirFluSal MDI 25 microgram/125 microgram per actuation — Summary of Product Characteristicselectronic Medicines Compendium · United Kingdom · dated 2026-06-19 · accessed not_supplied_in_research_notes · source 3
Brand names by country
Single-ingredient fluticasone propionate/salmeterol names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- ADVAIR DISKUS (1)current labelled product · 100 micrograms fluticasone propionate / 50 micrograms salmeterol per labelled blister, 250 micrograms fluticasone propionate / 50 micrograms salmeterol per labelled blister, 500 micrograms fluticasone propionate / 50 micrograms salmeterol per labelled blister · Not established in the supplied notes; see current FDA prescribing information
- Advair HFA (2)named in United States patient information; product details unresolved in supplied notes · not established in the supplied notes · Not established in the supplied notes
- AirDuo RespiClick (2)named in United States patient information; product details unresolved in supplied notes · not established in the supplied notes · Not established in the supplied notes
United Kingdom
- AirFluSal MDI (3)current licensed product · 25 micrograms salmeterol / 125 micrograms fluticasone propionate per metered actuation, 21 micrograms salmeterol / 110 micrograms fluticasone propionate per delivered dose · Not established in the supplied notes